Status:

UNKNOWN

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

Lead Sponsor:

Maxinovel Pty., Ltd.

Conditions:

Solid Tumor

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.

Detailed Description

This study is a study of Max-40279-01 in combination with toripalimab in patients with advanced solid tumors. This study includes two Parts, the Part 1 will assess the safety and efficacy of the prese...

Eligibility Criteria

Inclusion

  • Males and/or females over age 18
  • Histologically and/or cytologically documented local advanced or metastatic solid tumor.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Expected survival \>3 months.
  • Signed informed consent form.

Exclusion

  • Known uncontrolled or symptomatic central nervous system metastatic disease.
  • Adverse events (with exception of alopecia, peripheral sensory neuropathy grade ≤ 2 and those listed in specific exclusion criteria) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0) at the time of randomization.
  • Inadequate organ or bone marrow function.
  • Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  • Pregnant or breast-feeding woman.
  • Known allergies, hypersensitivity, or intolerance to Max-40279-01 the excipients of these treatments.

Key Trial Info

Start Date :

April 11 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 31 2023

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT05369286

Start Date

April 11 2022

End Date

August 31 2023

Last Update

May 11 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institute of The Sixth Affiliated Hospital Sun Yat-sen University

Guangzhou, Guangdong, China, 510000